p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix.

Kessis TD, Slebos RJ, Han SM, Shah K, Bosch XF, Muñoz N, Hedrick L, Cho KR
Am J Pathol. 1993 143 (5): 1398-405

PMID: 8238255 · PMCID: PMC1887168

The p53 gene is the most frequently altered gene known thus far in a wide variety of human cancers. Inactivation of p53, either through mutation or through interaction with the human papillomavirus (HPV) E6 oncoprotein, is a characteristic feature of all cervical carcinoma cell lines that have been studied. These findings suggest that p53 inactivation is required for cervical carcinoma development and that HPV infection and p53 mutation may be mutually exclusive. We have studied the p53 gene in 35 primary cervical carcinomas. DNA sequence and single strand conformational polymorphism analyses were used to evaluate p53 in 27 squamous carcinomas (25 HPV-positive) and eight adenocarcinomas (four HPV-positive). A missense mutation of p53 was observed in one HPV 16-positive squamous carcinoma, demonstrating that p53 mutations can occur in combination with HPV infection. The HPV-negative tumors all lacked p53 gene mutations. The absence of p53 mutations in HPV-negative cases prompted an assessment of tumors for MDM2 gene amplification. The MDM2 gene encodes a p53 binding protein and has been found to be amplified in some human tumors lacking p53 mutations. MDM2 amplification was not identified in any of the tumors we examined, including four HPV-negative cases. Our findings show that HPV infection and p53 gene mutation are not mutually exclusive and suggest that many HPV-negative carcinomas may arise via a pathway independent of p53 inactivation.

MeSH Terms (14)

Adenocarcinoma Base Sequence Carcinoma, Squamous Cell DNA, Viral DNA Mutational Analysis Female Gene Amplification Gene Deletion Genes, p53 Humans Molecular Sequence Data Papillomaviridae Sequence Analysis, DNA Uterine Cervical Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: